vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $253.4M, roughly 1.1× Palomar Holdings, Inc.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 9.4%). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
ACAD vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $253.4M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 28.7% |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | 62.7% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $253.4M | ||
| Q3 25 | $278.6M | $244.7M | ||
| Q2 25 | $264.6M | $203.3M | ||
| Q1 25 | $244.3M | $174.6M | ||
| Q4 24 | $259.6M | $155.8M | ||
| Q3 24 | $250.4M | $148.5M | ||
| Q2 24 | $242.0M | $131.1M | ||
| Q1 24 | $205.8M | $118.5M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $51.5M | ||
| Q2 25 | $26.7M | $46.5M | ||
| Q1 25 | $19.0M | $42.9M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $30.5M | ||
| Q2 24 | $33.4M | $25.7M | ||
| Q1 24 | $16.6M | $26.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 28.7% | ||
| Q3 25 | 12.8% | 27.4% | ||
| Q2 25 | 12.2% | 29.5% | ||
| Q1 25 | 7.9% | 30.8% | ||
| Q4 24 | 59.1% | 28.9% | ||
| Q3 24 | 12.6% | 25.9% | ||
| Q2 24 | 12.6% | 25.5% | ||
| Q1 24 | 7.4% | 29.0% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | 21.0% | ||
| Q2 25 | 10.1% | 22.9% | ||
| Q1 25 | 7.8% | 24.6% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 20.5% | ||
| Q2 24 | 13.8% | 19.6% | ||
| Q1 24 | 8.0% | 22.3% |
| Q4 25 | $1.61 | $2.05 | ||
| Q3 25 | $0.42 | $1.87 | ||
| Q2 25 | $0.16 | $1.68 | ||
| Q1 25 | $0.11 | $1.57 | ||
| Q4 24 | $0.86 | $1.29 | ||
| Q3 24 | $0.20 | $1.15 | ||
| Q2 24 | $0.20 | $1.00 | ||
| Q1 24 | $0.10 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $106.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $942.7M |
| Total Assets | $1.6B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $106.9M | ||
| Q3 25 | $258.0M | $111.7M | ||
| Q2 25 | $253.6M | $81.3M | ||
| Q1 25 | $217.7M | $119.3M | ||
| Q4 24 | $319.6M | $80.4M | ||
| Q3 24 | $155.1M | $86.5M | ||
| Q2 24 | $177.1M | $47.8M | ||
| Q1 24 | $204.7M | $61.4M |
| Q4 25 | $1.2B | $942.7M | ||
| Q3 25 | $917.3M | $878.1M | ||
| Q2 25 | $822.4M | $847.2M | ||
| Q1 25 | $765.2M | $790.4M | ||
| Q4 24 | $732.8M | $729.0M | ||
| Q3 24 | $577.2M | $703.3M | ||
| Q2 24 | $516.7M | $532.6M | ||
| Q1 24 | $464.0M | $501.7M |
| Q4 25 | $1.6B | $3.1B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.8B | ||
| Q1 25 | $1.1B | $2.4B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $976.9M | $2.3B | ||
| Q2 24 | $914.1M | $2.0B | ||
| Q1 24 | $855.1M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $409.1M |
| Free Cash FlowOCF − Capex | — | $409.0M |
| FCF MarginFCF / Revenue | — | 161.4% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $409.1M | ||
| Q3 25 | $74.3M | $83.6M | ||
| Q2 25 | $64.0M | $120.9M | ||
| Q1 25 | $20.3M | $87.2M | ||
| Q4 24 | $40.4M | $261.2M | ||
| Q3 24 | $63.2M | $100.3M | ||
| Q2 24 | $25.0M | $55.1M | ||
| Q1 24 | $29.1M | $33.1M |
| Q4 25 | — | $409.0M | ||
| Q3 25 | $73.9M | $83.6M | ||
| Q2 25 | — | $120.8M | ||
| Q1 25 | — | $87.1M | ||
| Q4 24 | — | $260.9M | ||
| Q3 24 | $63.2M | $100.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 161.4% | ||
| Q3 25 | 26.5% | 34.2% | ||
| Q2 25 | — | 59.4% | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | 167.5% | ||
| Q3 24 | 25.2% | 67.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 1.63× | ||
| Q2 25 | 2.40× | 2.60× | ||
| Q1 25 | 1.07× | 2.03× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 3.29× | ||
| Q2 24 | 0.75× | 2.14× | ||
| Q1 24 | 1.76× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PLMR
Segment breakdown not available.
